Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AQ001M
- Development stage
- Preclinical
- Lead developer
- Aquilon Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
AQ001M is a reformulated budesonide inhalation product developed by Aquilon Pharmaceuticals for the treatment of asthma. It utilizes a proprietary cyclodextrin-based excipient technology (HP-Betadex complex) to solubilize budesonide in water, enabling ultra-low dose delivery to the deep lung via soft mist inhalers. By improving the pharmacology and lung deposition of the corticosteroid compared to conventional products, AQ001M aims to reduce airway inflammation through the activation of the glucocorticoid receptor while potentially minimizing systemic side effects associated with higher doses.
- Other names
- budesonide
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on AQ001M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AQ001M.